Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $1.1152W HIGH $2.95
Volume
3.83 K
Value Traded
30.00 K
Short % Float
0.23%
Days to Cover
1.4
0%Week
-11.33%1 Month
-11.76%3 Month
-10.89%6 Month
-96.58%5 Year
-99.88%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
20.83 M
EPS (TTM)
-0.02
P/E Ratio
-
Ent. Value
11.64 M
Total Shares
11.58 M
Float Shares
10.60 M
Insiders
8.45%
Institutions
31.68%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
TXMD Catalyst Timeline
Dated clinical, regulatory and corporate events for TherapeuticsMD, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for TherapeuticsMD, Inc.
475Total events
1Upcoming
110Tier-1 (high impact)
2012 to 2026Coverage
Upcoming catalysts 1
TBD
T2Timing Guidance
Subscribe to view catalyst details
Event history 50
▲Milestone PaymentIMVEXXYApprovedCorporate
Knight Therapeutics notifies achievement of IMVEXXY net sales milestone for 2025, triggering CAD 500 thousand payment
▲Timing GuidanceIMVEXXYApprovedPresentation
Milestone revenue to be recognized in third quarter of 2026
●Management ChangeCorporate
Board resignations and appointment of new Principal Executive Officer
▼Restructuring LayoffsCorporate
Termination of executive management team and all other employees completed
▲Partnership / LicenseCorporate
Exclusive license to commercialize Imvexxy, Bijuva, BocaGreenMD, vitaMedMD, and Annovera in the US granted to Mayne Pharma
▲Debt Royalty FinancingCorporate
Repayment of all obligations under Financing Agreement with Sixth Street Specialty Lending
▼Equity OfferingCorporate
Additional $7 million private placement of Series A Preferred Stock from Rubric Capital Management
●Debt Royalty FinancingCorporate
Maturity date of financing agreement with Sixth Street extended to November 30, 2022
▼Equity OfferingCorporate
Received $7 million private investment in Series A Preferred Stock from Rubric Capital Management
●Debt Royalty FinancingCorporate
Maturity date of financing agreement with Sixth Street extended to October 31, 2022, with option to extend to November 30, 2022
◆Debt Royalty FinancingCorporate
Extension of financing agreement maturity to September 30, 2022 with option to extend to November 30, 2022
◆Management ChangeCorporate
Appointment of Dr. Brian Bernick and Mr. Mark Glickman as Interim Co-CEOs
▲Quarterly UpdateANNOVERAApprovedCorporate
ANNOVERA TRx of 9,329, 28% increase over Q2 2021
contraceptionsource ↗
▲Supplemental ApprovalANNOVERAApprovedFDA Decision
FDA approval of sNDA for ANNOVERA with minor revisions to in vitro release testing specification
birth controlsource ↗
▲Supply DisruptionANNOVERAApprovedCMC / Inspection
Approximately 7,000 additional rings expected to enter supply chain in Q2 and Q3 2022
birth controlsource ↗
●Oral PresentationPresentation
Conference call to discuss Q4 2021 financial results and business update
▲Partnership / LicenseCorporate
TherapeuticsMD enters definitive agreement to divest vitaCare to GoodRx for $150M cash plus up to $7M contingent consideration
▲FDA ApprovalANNOVERAApprovedFDA Decision
FDA approval of supplemental new drug application for ANNOVERA
contraceptionsource ↗
Past FDA Catalysts and PDUFA Decisions
How TXMD actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2021-12-10 | ANNOVERA (segesterone acetate / ethinyl estradiol vaginal system) | PDUFA Date CRL | PDUFA |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
4
Drugs Scored
rNPV / MCap
Top Drug
Top 80%
Micro Cap(rank 526 of 657)
Percentile Rank
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|
Clinical Trial Results
Readouts, endpoints and source filings for every TXMD program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| TX-001HR | moderate to severe vasomotor symptoms (VMS) | Phase 3 | 2016-12-05 | doses: estradiol 1 mg, progesterone 100 mg, n 416, estradiol 0.5 mg, progesterone 100 mg, n 423, estradiol 0.5 mg, progesterone 50 mg, n 421, estradiol 0.25 mg, progesterone 50 mg, n 424; adverse events: headache, nasopharyngitis, breast tenderness, upper respiratory infectionRead More | TherapeuticsMD Announces Positive Top-Line Results from Pivotal Phase 3 Replenish Trial in Postmenopausal Women with Moderate to Severe Vasomotor Symptoms (VMS) Treated with TX-001HR - TX-001HR, theRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Thompson Tommy GDirector | Buy | 8,400 23,179 held | $1.67 | 12/23/2025 |
Hedge Fund 13F Activity
Hedge Funds invested in TXMD
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 0.1 % (-50 %) | 9.30 M | 7.81 M |
TXMD Institutional Ownership Trends
TXMD Short Interest
Shares sold short, counted twice a month.
0.23%
Short % of Float
of tradable shares sold short
24.7K
Shares Sold Short
+4.2% vs prior count
1.4 Low
Days to Cover
trading days of normal volume to buy every short share back
17.3K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How TXMD ranks across every disease it competes in
Competitive Position is a premium feature
See how TXMD ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialTXMD News
TXMDTherapeuticsMD Announces Second Quarter 2026 Financial Results
TherapeuticsMD, Inc. reported its financial results for the second quarter of 2026, showing a net income of $164 thousand, a decrease from $545 thousand in the same period of 2025. The report highlights a decline in profitability, raising concerns about the company's financial performance. The company continues to manage its pharmaceutical royalty rights amid these challenges.
Read more →TXMDTherapeuticsMD Announces First Quarter 2026 Financial Results
TherapeuticsMD has announced its financial results for the first quarter of 2026. However, the article does not provide specific details regarding the performance metrics or any significant developments related to the company's operations. The lack of detailed information limits the insight into the company's current standing.
Read more →TXMD▼ -5.2%on this news
TherapeuticsMD Announces Full Year 2025 Financial Results
TherapeuticsMD has announced its financial results for the full year 2025. The article provides an overview of the company's performance, but lacks detailed insights into specific financial metrics or strategic developments. Further analysis may be needed to understand the implications of these results on the company's future.
Read more →TXMDTherapeuticsMD Announces Third Quarter 2025
TherapeuticsMD, Inc. has announced its financial results for the third quarter of 2025, showing a transition from a women's healthcare company to a pharmaceutical royalty model. This change entails a focus on collecting royalties rather than engaging in research and development. The company also highlighted the continued exploration of strategic alternatives amidst various operational risks, including commercialization challenges and ongoing disputes with partners.
Read more →TXMDTherapeuticsMD Announces Second Quarter 2025
TherapeuticsMD, Inc. recently reported its financial results for the second quarter of 2025, marking a shift in its business model from a women's healthcare company to a pharmaceutical royalty entity. Despite the change, the company faces several challenges, including uncertainties surrounding its licensees' success and the winding down of its previous operations. The exploration of strategic alternatives, such as acquisitions or mergers, may offer potential pathways to enhance shareholder value. However, these efforts come with inherent risks, particularly relating to operational transition and market performance.
Read more →TXMDTherapeuticsMD Announces First Quarter 2025 Financial Results
TherapeuticsMD, Inc. announced its financial results for Q1 2025, revealing a loss from continuing operations and an ongoing transition to a pharmaceutical royalty company after previously focusing on women's healthcare. The company is not engaging in research and development anymore, instead collecting royalties from licensees. This shift in business strategy raises uncertainties surrounding the company's future performance and potential challenges in retaining its Nasdaq listing. Additionally, disputes with Mayne Pharma add further risks to the company's outlook.
Read more →TXMDTherapeuticsMD Announces Full Year 2024 Financial
TherapeuticsMD, Inc. reported its financial results for the full year ending December 31, 2024, indicating a net loss from continuing operations. The company has shifted its focus from women's healthcare to a pharmaceutical royalty model, ending its research and development activities. This transition raises concerns about future business opportunities and reliance on the success of licensees to drive revenue. Forward-looking statements highlight the company's exploration of strategic alternatives in the face of significant operational changes.
Read more →TXMDTherapeuticsMD Announces Third Quarter 2024
TherapeuticsMD, Inc. announced its financial results for the third quarter of 2024, highlighting a transition from a women's healthcare firm to a pharmaceutical royalty company. The company reported license and service revenues but is ceasing its research and development efforts. TherapeuticsMD is currently exploring strategic alternatives, which may include mergers or acquisitions. The firm faces risks regarding the commercialization success of its licensees and maintaining its Nasdaq listing.
Read more →TXMDTherapeuticsMD Announces Second Quarter 2024
TherapeuticsMD, Inc. reported its second quarter 2024 financial results, showing net losses from continuing operations. The company, now operating as a pharmaceutical royalty firm, has transitioned from its previous focus on women's healthcare. It is currently assessing various strategic alternatives, which may include acquisitions or other transactions, to enhance shareholder value. Ongoing challenges include the success of its licensees in commercializing products and the costs associated with winding down previous operations.
Read more →TXMDTherapeuticsMD Announces First Quarter 2024 Financial
TherapeuticsMD, Inc. announced its financial results for the first quarter of 2024, marking a significant transition from a women's healthcare focus to a pharmaceutical royalty model. While the company is exploring strategic alternatives such as potential acquisitions and other business combinations, it faces substantial challenges as it has ceased research and development activities. Additionally, there are concerns over the commercial success of its licensees and the operational costs tied to winding down previous operations.
Read more →TXMDTherapeuticsMD Announces Full Year 2023 Financial Results
TherapeuticsMD, Inc. has announced its financial results for the full year ended December 31, 2023, while continuing to explore a variety of strategic alternatives aimed at maximizing shareholder value. Following its shift from a women's healthcare focus to a pharmaceutical royalty business model in December 2022, the company is no longer involved in research and development. The CEO, Marlan D. Walker, indicated that the company is committed to reviewing options such as acquisitions, mergers, or asset sales. The transition raises concerns regarding operational execution and financial stability as it relies on its licensees for revenue.
Read more →TXMDTherapeuticsMD Announces Third Quarter 2023 Financial Results Focus remains on cost control to maximize the value of our royalty assets Company announces evaluation of strategic alternatives
TherapeuticsMD reported its third quarter 2023 financial results, indicating a continued focus on cost control and maximizing the value of its royalty assets. The company, which has transitioned from a women's healthcare focus to primarily collecting pharmaceutical royalties, also announced an evaluation of strategic alternatives. Current financial results reflect a net loss from continuing operations, highlighting the challenges faced during this transition. The management team underscored their commitment to exploring potential strategic options to enhance shareholder value.
Read more →TXMDTherapeuticsMD Announces Second Quarter 2023 Financial Results
TherapeuticsMD reported its financial results for Q2 2023, highlighting a net loss from continuing operations. The company is transitioning from a women's healthcare focus to a royalty-based business model and is currently working on cost reduction. However, it faces uncertainties, particularly concerning the commercialization of its licensed products and ongoing operational wind-down costs.
Read more →TXMDTherapeuticsMD Announces First Quarter 2023 Financial Results
TherapeuticsMD (TXMD) announced its financial results for the first quarter of 2023, highlighting its transition from a women's healthcare company to a pharmaceutical royalty model. The company is winding down its former operations and focusing on cost reduction. This shift raises concerns about its ability to generate revenue and maintain stability. Additionally, TXMD's future performance is contingent on the success of its partner, Mayne Pharma, which adds further risk amid ongoing uncertainties.
Read more →TXMDTherapeuticsMD Announces Full Year 2022 Financial Results and Provides Update on Business Model Transition
TherapeuticsMD, Inc. reported its financial results for the full year 2022 and announced its transition to a virtual business model following a transaction with Mayne Pharma. During this process, TherapeuticsMD eliminated its commercial and manufacturing infrastructure and downsized to one full-time employee. The transaction included a $140 million upfront payment, as well as future royalties from the sale of its products. The company is actively seeking strategic avenues to enhance shareholder value despite operational downsizing and potential risks associated with future commercialization success.
Read more →TXMD▲ +11.8%on this news
TherapeuticsMD Completes Transaction to License its Products to Mayne Pharma - Mayne Pharma gains exclusive U.S. commercialization rights for TXMD s products and acquires certain assets - - TXMD received approximately $1
TherapeuticsMD has completed a transaction to license its products to Mayne Pharma, granting the latter exclusive commercialization rights in the U.S. TXMD received approximately $153.1 million at closing, which will be used to repay outstanding debts and redeem preferred stock. The deal also provides TXMD with the potential for additional milestone and royalty payments over the coming years. Several board members resigned as part of the transaction, raising concerns about future leadership stability.
Read more →TXMDUnaudited Pro Forma Condensed Consolidated Financial Information Overview Effective
Unaudited Pro Forma Condensed Consolidated Financial Information Effective December 30, 2022 (the Closing Date ), TherapeuticsMD, Inc., a Nevada corporation (the Company ), completed its previously announced transaction (the Transaction ) with Mayne Pharma LLC, a Delaware limit
Read more →TXMD▲ +15.1%on this news· ran to +34% by day 3
TherapeuticsMD Announces Definitive Agreements to License its Products to Mayne Pharma - TXMD to receive approximately $153.1 million in consideration at closing (including approximately $13.1 million for acquired net wo
TherapeuticsMD Announces Definitive Agreements to License its Products to Mayne Pharma - TXMD to receive approximately $153.1 million in consideration at closing (including approximately $13.1 million for acquired net working capital), up to approximately $42.6 million in minim
Read more →TXMD▼ -7.4%on this news· ran to -24% by day 3
TherapeuticsMD Announces Third Quarter 2022 Financial Results - Q3 total revenue of $20.9 million - - ANNOVERA TRx growth of 10% year-over-year - - Reduced operating expenses by $22 million year-over-year
TherapeuticsMD Announces Third Quarter 2022 Financial Results - Q3 total revenue of $20.9 million - - ANNOVERA TRx growth of 10% year-over-year - - Reduced operating expenses by $22 million year-over-year - BOCA RATON, Fla. - November 14, 2022 - TherapeuticsMD, Inc. ("TXMD" o
Read more →TXMD▲ +6.2%on this news
TherapeuticsMD Announces Additional $7 Million Private Placement Maturity Date of Financing Agreement Extended to
TherapeuticsMD Announces Additional $7 Million Private Placement Maturity Date of Financing Agreement Extended to November 30, 2022 BOCA RATON, Fla. October 31, 2022 TherapeuticsMD, Inc. (NASDAQ: TXMD), ( TherapeuticsMD or the Company ) an innovative, leading women s healthcar
Read more →About TherapeuticsMD, Inc.
Headquarters951 YAMATO ROAD, SUITE 220, BOCA RATON, FL, 33431
BIOPHARMAWATCH ELITE PLUS
Trade the next TXMD catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime